Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mike Bayne"'
Autor:
Joanna Hack, Mike Bayne
Publikováno v:
Lung Cancer. 165:S74-S75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f5a8c80164b805be5d5b6c88541a59a
https://doi.org/10.1016/s0169-5002(22)00208-2
https://doi.org/10.1016/s0169-5002(22)00208-2
Autor:
Unn-Merete Fagerli, Nils Bolstad, Arne Kolstad, Ayca Løndalen, Noelle O'Rourke, Aleš Obr, Timothy M Illidge, Michal Kaščák, Caroline Stokke, Johan Blakkisrud, Ulf Madsbu, Lisa Rojkjaer, Veronique Pascal, Wojciech Jurczak, Harald Holte, Matthew Beasley, Signe Spetalen, Jostein Dahle, Mike Bayne
Publikováno v:
Blood Adv
Kolstad, A, Illidge, T, Bolstad, N, Spetalen, S, Madsbu, U, Stokke, C, Blakkisrud, J, Løndalen, A, O'Rourke, N, Beasley, M, Jurczak, W, Fagerli, U-M, Kaščák, M, Bayne, M, Obr, A, Dahle, J, Rojkjaer, L, Pascal, V & Holte, H 2020, ' Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma ', Blood Advances, vol. 4, no. 17, pp. 4091-4101 . https://doi.org/10.1182/bloodadvances.2020002583
Kolstad, A, Illidge, T, Bolstad, N, Spetalen, S, Madsbu, U, Stokke, C, Blakkisrud, J, Løndalen, A, O'Rourke, N, Beasley, M, Jurczak, W, Fagerli, U-M, Kaščák, M, Bayne, M, Obr, A, Dahle, J, Rojkjaer, L, Pascal, V & Holte, H 2020, ' Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma ', Blood Advances, vol. 4, no. 17, pp. 4091-4101 . https://doi.org/10.1182/bloodadvances.2020002583
For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20–based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0f06b790f4a6ad159af93e4af50b9e4
https://pubmed.ncbi.nlm.nih.gov/32877524
https://pubmed.ncbi.nlm.nih.gov/32877524
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b560648f72d5cf403d01ac2c7347b980
https://doi.org/10.1530/endoabs.52.p07
https://doi.org/10.1530/endoabs.52.p07
Autor:
Emmilia Hodak, Evangelia Papadavid, Pietro Quaglino, Miles Prince, Maarten Vermeer, Christiane Querfeld, René Stranzenbach, Fiona Child, Sean Whittaker, Vijaytha Muralidharan, Martine Bagot, Pablo Ortiz, Rudolf Stadler, Robert Knobler, Emmanuella Guenova, Teresa Estrach, Aikaterina Patsatsi, Emilio Berti, Silvia Alberti-Violetti, Richard Cowan, Constanze Jonak, Vasiliki Nikolaou, Christina Mitteldorf, Rubeta Matin, Marie Beylot-Barry, Liisa Vakeva, Jose Antonio Sanches, Octavio Servitje, Sophie Weatherhead, Marion Wobser, Jinah Yoo, Mike Bayne, Andrew Bates, Giles Dunnill, Marta Marschalko, Anne-Marie Buschots, Ulrike Wehkamp, Rachel Wachsmuth, Arvind Arumainathan, Antonio Cozzio, Oleg Akilov, Werner Kempf, Lorenzo Cerroni, Felicity Evison, E. Hong, Rein Willemze, Youn Kim, Julia Scarisbrick
Publikováno v:
European Journal of Cancer. 101:S25-S26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d75d066e0b17e9c5691217f6bab64b
https://doi.org/10.1016/j.ejca.2018.07.274
https://doi.org/10.1016/j.ejca.2018.07.274
Autor:
Harald Holte, Nils Bolstad, A. Muftuler Londalen, Arne Kolstad, Mike Bayne, Stine Nygaard, Martin Erlanson, Ella Willenbacher, M. Bloma, Wojciech Jurczak, Matthew Beasley, Signe Spetalen, Lisa Rojkjaer, Johan Blakkisrud, Ulf Madsbu, Noelle O'Rourke, Timothy M Illidge, Ingemar Lagerlöf, Simon Turner, Roman Hájek, L. Baylor Curtis
Publikováno v:
Hematological Oncology. 35:269-270
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f05007c8b8fa5bf108c1af093d70e934
https://doi.org/10.1002/hon.2438_142
https://doi.org/10.1002/hon.2438_142
Autor:
Timothy M Illidge, Mike Bayne
Publikováno v:
Clinical Oncology. 13:372-377
Hypercalcaemia is the most common serious metabolic complication of malignancy. Recent advances have significantly increased our understanding of the pathophysiology of hypercalcaemia of malignancy and revealed the importance of parathyroid hormone-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35a3d7f8bc1723b0f2287250062a090d
https://doi.org/10.1053/clon.2001.9293
https://doi.org/10.1053/clon.2001.9293
Autor:
Tim M, Illidge, Sam, Mayes, Ruth, Pettengell, Andrew T, Bates, Mike, Bayne, John A, Radford, W David J, Ryder, Steven, Le Gouill, Fabrice, Jardin, Jill, Tipping, Maureen, Zivanovic, Françoise, Kraeber-Bodere, Manuel, Bardies, Caroline, Bodet-Milin, Emmanuel, Malek, Damien, Huglo, Franck, Morschhauser
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(3)
We report an international, multicenter phase II trial to evaluate the efficacy and toxicity of fractionated (90)Y-ibritumomab tiuxetan ((90)Y-IT) as initial therapy of follicular lymphoma (FL).A total of 74 patients, with a median age of 61 years (r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::23f06a40181e861b6515033120bfb523
https://pubmed.ncbi.nlm.nih.gov/24343668
https://pubmed.ncbi.nlm.nih.gov/24343668
Autor:
Thomas Valerius, Peter Johnson, Martin J. Glennie, Mike Bayne, Timothy M Illidge, Mark S. Cragg
Publikováno v:
Blood. 103:3989-3991
We read with interest the paper from Jilani et al[1][1] in which rituximab treatment appeared to down-modulate CD20 expression through a combination of internalization and RNA regulation. The result is unexpected because previous studies had shown th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dec213a08c53b723b6549c17699a70da
https://doi.org/10.1182/blood-2003-12-4384
https://doi.org/10.1182/blood-2003-12-4384
Autor:
Yong Du, Mike Bayne, Mark S. Cragg, Peter Johnson, Timothy M Illidge, Jamie Honeychurch, Martin J. Glennie
Publikováno v:
Blood. 103(4)
Radioimmunotherapy (RIT) has emerged as an effective treatment for lymphoma, however the underlying mechanisms are poorly understood. We therefore investigated the relative contributions of antibody and targeted radiation to the clearance of tumor in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a65d7428922e52f13898e3f4a5a78d73
https://pubmed.ncbi.nlm.nih.gov/14576070
https://pubmed.ncbi.nlm.nih.gov/14576070
Autor:
Mike Bayne, Timothy M Illidge
Publikováno v:
Expert opinion on pharmacotherapy. 2(6)
The availability of rituximab and the possible imminent availability of two new radiolabelled monoclonal anti-CD20 antibodies (Yttrium-90 (90Y)-ibritumomab and Iodine-131(131I)-tositumomab) have captured much attention in the treatment of lymphoma. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a03acbc89880e00cad79011c87939235
https://pubmed.ncbi.nlm.nih.gov/11585011
https://pubmed.ncbi.nlm.nih.gov/11585011